(Reuters) - Pfizer Inc's pain drug Lyrica won expanded U.S. approval to treat nerve pain associated with spinal cord injuries, the world's largest drugmaker said on Thursday. The additional approval ...

NEW YORK (CBS.MW) -- Pfizer Inc.'s shares dipped Friday, getting no lift from federal approval granted for the company to market its Lyrica drug as a treatment for nerve pain related to diabetes and ...

NEW YORK (CBS.MW) -- Pfizer shares were off 16 cents to $32.19 in late action. The New York pharmaceutical company has issued a statement on the regulatory status of its Lyrica drug in response to ...

In a blow for the U.S. drugmaker, Pfizer lost a yearslong patent battle for its blockbuster pain drug Lyrica after the U.K. Supreme Court ruled against it Nov. 14, according to Reuters. Lyrica, a $5 ...

Pfizer Inc. PFE announced that its epilepsy drug, Lyrica (pregabalin), failed to meet primary endpoint in a phase III study, evaluating it as adjunctive therapy in epilepsy patients (aged 5 to 65 ...

Billions in federal research grants frozen under the Trump administration threaten university labs that helped create drugs ...

LONDON (Reuters) - Pfizer lost the final round in a long-running patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain ...

ALEXANDRIA, Va. A review of previous studies by the journal Diabetes Care indicates that Pfizer’s seizure drug Lyrica is safe and effective for relieving diabetic neuropathy, the pain that diabetics ...

LONDON, Sept 10 (Reuters) - Pfizer suffered a major setback in Britain on Thursday when the High Court in London ruled that claims of patent protection for the use of its $5 billion-a-year drug Lyrica ...